000756 新华制药
已收盘 03-28 15:00:00
资讯
新帖
简况
新华制药(000756)3月27日主力资金净卖出5070.14万元
证券之星 · 09:22
新华制药(000756)3月27日主力资金净卖出5070.14万元
新华制药(000756)2月28日股东户数15.01万户,较上期增加39.94%
证券之星 · 03-27 16:58
新华制药(000756)2月28日股东户数15.01万户,较上期增加39.94%
新华制药最新公告:美洛昔康胶囊通过仿制药一致性评价
证券之星 · 03-27 16:50
新华制药最新公告:美洛昔康胶囊通过仿制药一致性评价
公告精选︱文灿股份与蔚来签战略合作框架协议;中国石化拟向控股股东增发A股募资不超120亿元
格隆汇 · 03-26 21:38
公告精选︱文灿股份与蔚来签战略合作框架协议;中国石化拟向控股股东增发A股募资不超120亿元
图解新华制药年报:第四季度单季净利润同比增86.28%
证券之星 · 03-26 18:32
图解新华制药年报:第四季度单季净利润同比增86.28%
新华制药最新公告:2022年净利同比增长18%
证券之星 · 03-26 17:09
新华制药最新公告:2022年净利同比增长18%
新华制药(000756.SZ)发布2022年度业绩,净利润4.11亿元,同比增长17.97%,拟10派2元
智通财经网 · 03-26 16:35
新华制药(000756.SZ)发布2022年度业绩,净利润4.11亿元,同比增长17.97%,拟10派2元
新华制药最新公告:乙酰胺化学原料药上市申请获批
证券之星 · 03-16
新华制药最新公告:乙酰胺化学原料药上市申请获批
新华制药(000756.SZ)取得碳酸司维拉姆片药品注册证书
智通财经网 · 02-27
新华制药(000756.SZ)取得碳酸司维拉姆片药品注册证书
抗疫概念股拉升,国内新冠疫情不确定性或带动新冠小分子需求
格隆汇 · 02-22
抗疫概念股拉升,国内新冠疫情不确定性或带动新冠小分子需求
2月17日新华制药涨停分析:新冠药物,维生素,医药概念热股
证券之星 · 02-17
2月17日新华制药涨停分析:新冠药物,维生素,医药概念热股
异动快报:新华制药(000756)2月17日13点21分触及涨停板
证券之星 · 02-17
异动快报:新华制药(000756)2月17日13点21分触及涨停板
【AH互动】新华制药(00719)AH股齐上扬 吡拉西坦注射液通过仿制药一致性评价
凤凰网港股 · 02-16
【AH互动】新华制药(00719)AH股齐上扬 吡拉西坦注射液通过仿制药一致性评价
新华制药(000756.SZ):吡拉西坦注射液通过仿制药一致性评价
智通财经网 · 02-15
新华制药(000756.SZ):吡拉西坦注射液通过仿制药一致性评价
新华制药:吡拉西坦注射液通过仿制药一致性评价
财联社 · 02-15
新华制药:吡拉西坦注射液通过仿制药一致性评价
新华制药:取得加工阿兹夫定片所需的《药品生产许可证》C证
财联社 · 01-18
新华制药:取得加工阿兹夫定片所需的《药品生产许可证》C证
新华制药(000756.SZ):OAB-14干混悬剂药物临床试验获批
智通财经 · 01-12
新华制药(000756.SZ):OAB-14干混悬剂药物临床试验获批
板块异动 | 阿兹夫定参与医保药品目录谈判成功 新冠药概念股尾盘拉升
智通财经 · 01-09
板块异动 | 阿兹夫定参与医保药品目录谈判成功 新冠药概念股尾盘拉升
不用抢了?退烧药、抗原短缺状况已缓解 京沪基层正陆续配备新冠口服药|传真
财联社 · 01-06
不用抢了?退烧药、抗原短缺状况已缓解 京沪基层正陆续配备新冠口服药|传真
格隆汇公告精选︱康希诺:新冠mRNA疫苗在临床研究中取得了积极的阶段性数据;尚太科技:锂离子电池负极材料项目仍处于论证阶段
格隆汇 · 01-06
格隆汇公告精选︱康希诺:新冠mRNA疫苗在临床研究中取得了积极的阶段性数据;尚太科技:锂离子电池负极材料项目仍处于论证阶段
加载更多
公司概况
公司名称:
山东新华制药股份有限公司
所属行业:
医药制造业
上市日期:
1997-08-06
主营业务:
山东新华制药股份有限公司主要从事开发、制造及销售化学原料药、制剂以及化工产品;公司的主要产品有解热镇痛类原料药、片剂、针剂、胶囊剂、医药中间体。公司拥有技术创新优势,现为高新技术企业、国家火炬计划重点高新技术企业、国家火炬计划生物医药产业基地骨干企业,拥有国家级企业技术中心,建有企业博士后科研工作站。“基于产业化关键技术的咖啡因绿色制备体系构建与规模开发”荣获2018年度山东省科学技术进步二等奖。上半年获得专利授权10件。公司被公示为“山东省技术创新示范企业”,被评为山东人才工作先进单位。
发行价格:
3.45
{"stockData":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"新华制药","latestPrice":24.87,"timestamp":1679987001000,"preClose":25.33,"halted":0,"volume":15758059,"delay":0,"floatShares":441000000,"shares":674000000,"eps":0.7032,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.46,"latestTime":"03-28 15:00:00","open":25.34,"high":25.5,"low":24.81,"amount":394000000,"amplitude":0.0272,"askPrice":24.88,"askSize":226,"bidPrice":24.87,"bidSize":85,"shortable":0,"etf":0,"ttmEps":0.7032,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1680053400000},"adr":0,"adjPreClose":25.33,"symbolType":"stock","highLimit":27.86,"lowLimit":22.8,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":673887535,"pbRate":4.14,"roa":"--","roe":"10.62%","epsLYR":0.62,"committee":0.314451,"marketValue":16760000000,"floatMarketCap":10958000000,"peRate":35.366895,"changeRate":-0.0182,"turnoverRate":0.0358,"status":1},"requestUrl":"/m/hq/s/000756/","defaultTab":"news","newsList":[{"id":"2322400436","title":"新华制药(000756)3月27日主力资金净卖出5070.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2322400436","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2322400436?lang=zh_CN&edition=full","pubTime":"2023-03-28 09:22","pubTimestamp":1679966537,"startTime":"0","endTime":"0","summary":"截至2023年3月27日收盘,新华制药报收于25.33元,下跌2.5%,换手率3.6%,成交量15.88万手,成交额4.03亿元。近5日资金流向一览见下表:新华制药融资融券信息显示,融资方面,当日融资买入1933.46万元,融资偿还2996.64万元,融资净偿还1063.18万元。新华制药主营业务:开发、制造和销售化学原料药、医药制剂、化工及其他产品。。根据近五年财报数据,证券之星估值分析工具显示,新华制药行业内竞争力的护城河良好,盈利能力较差,营收成长性一般。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032800012996.shtml","is_publish_highlight":false},{"id":"2322928445","title":"新华制药(000756)2月28日股东户数15.01万户,较上期增加39.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2322928445","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2322928445?lang=zh_CN&edition=full","pubTime":"2023-03-27 16:58","pubTimestamp":1679907502,"startTime":"0","endTime":"0","summary":"近日新华制药披露,截至2023年2月28日公司股东户数为15.01万户,较12月31日增加4.28万户,增幅为39.94%。在化学制药行业个股中,新华制药股东户数高于行业平均水平,截至2月28日,化学制药行业平均股东户数为3.94万户。从股价来看,2022年12月31日至2023年2月28日,新华制药区间涨幅为4.85%,在此期间股东户数增加0户,增幅为39.94%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032700013821.shtml","is_publish_highlight":false},{"id":"2322944319","title":"新华制药最新公告:美洛昔康胶囊通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2322944319","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2322944319?lang=zh_CN&edition=full","pubTime":"2023-03-27 16:50","pubTimestamp":1679907023,"startTime":"0","endTime":"0","summary":"新华制药公告,公司收到国家药品监督管理局核准签发的美洛昔康胶囊《药品补充申请批准通知书》,该产品通过仿制药质量和疗效一致性评价。截至2023年3月27日收盘,新华制药报收于25.33元,下跌2.5%,换手率3.6%,成交量15.88万手,成交额4.03亿元。根据近五年财报数据,证券之星估值分析工具显示,新华制药行业内竞争力的护城河良好,盈利能力较差,营收成长性一般。新华制药主营业务:开发、制造和销售化学原料药、医药制剂、化工及其他产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032700013241.shtml","is_publish_highlight":false},{"id":"2322459819","title":"公告精选︱文灿股份与蔚来签战略合作框架协议;中国石化拟向控股股东增发A股募资不超120亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2322459819","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2322459819?lang=zh_CN&edition=full","pubTime":"2023-03-26 21:38","pubTimestamp":1679837932,"startTime":"0","endTime":"0","summary":"杉杉股份(600884.SH):新任董事长选举合法有效;寒武纪(688256.SH):网络传闻百度\"文心一言\"已使用公司产品等市场传闻不属实","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/111.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/589153","is_publish_highlight":false},{"id":"2322430236","title":"图解新华制药年报:第四季度单季净利润同比增86.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2322430236","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2322430236?lang=zh_CN&edition=full","pubTime":"2023-03-26 18:32","pubTimestamp":1679826774,"startTime":"0","endTime":"0","summary":"新华制药2022年报显示,公司主营收入75.03亿元,同比上升14.37%;归母净利润4.11亿元,同比上升17.97%;扣非净利润3.79亿元,同比上升29.97%;其中2022年第四季度,公司单季度主营收入20.5亿元,同比上升26.53%;单季度归母净利润1.18亿元,同比上升86.28%;单季度扣非净利润1.1亿元,同比上升180.06%;负债率47.37%,投资收益836.5万元,财务费用3201.95万元,毛利率27.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032600000736.shtml","is_publish_highlight":false},{"id":"2322112432","title":"新华制药最新公告:2022年净利同比增长18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2322112432","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2322112432?lang=zh_CN&edition=full","pubTime":"2023-03-26 17:09","pubTimestamp":1679821788,"startTime":"0","endTime":"0","summary":"新华制药披露年报,公司2022年实现营业收入75.03亿元,同比增长14.37%;净利润4.11亿元,同比增长17.97%;基本每股收益0.62元。截至2023年3月24日收盘,新华制药报收于25.98元,下跌0.57%,换手率3.33%,成交量14.66万手,成交额3.79亿元。根据近五年财报数据,证券之星估值分析工具显示,新华制药行业内竞争力的护城河良好,盈利能力较差,营收成长性良好。以上内容由证券之星根据公开信息整理,与本站立场无关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032600000429.shtml","is_publish_highlight":false},{"id":"2322434282","title":"新华制药(000756.SZ)发布2022年度业绩,净利润4.11亿元,同比增长17.97%,拟10派2元","url":"https://stock-news.laohu8.com/highlight/detail?id=2322434282","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2322434282?lang=zh_CN&edition=full","pubTime":"2023-03-26 16:35","pubTimestamp":1679819744,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药 披露2022年年度报告,报告期公司实现营收75.03亿元,同比增长14.37%;归母净利润4.11亿元,同比增长17.97%;扣非净利润3.79亿元,同比增长29.97%;基本每股收益0.62元。公司拟向全体股东派发2022年末期股息每股0.2元(含税)。保持主导原料药市场稳定,全年原料药境内外销售额均实现两位数增长。抢抓市场机遇,医药中间体销售额同比增长21%。新华健康聚焦核心业务,实现多轨道快速发展,销售额同比增长28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/898776.html","is_publish_highlight":false},{"id":"2319335018","title":"新华制药最新公告:乙酰胺化学原料药上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2319335018","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2319335018?lang=zh_CN&edition=full","pubTime":"2023-03-16 17:02","pubTimestamp":1678957377,"startTime":"0","endTime":"0","summary":"新华制药公告,公司取得乙酰胺化学原料药上市申请批准通知书。截至2023年3月16日收盘,新华制药报收于26.7元,下跌2.94%,换手率3.8%,成交量16.76万手,成交额4.52亿元。根据近五年财报数据,证券之星估值分析工具显示,新华制药行业内竞争力的护城河良好,盈利能力较差,营收成长性良好。新华制药主营业务:开发、制造和销售化学原料药、医药制剂、化工及其他产品。以上内容由证券之星根据公开信息整理,与本站立场无关。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023031600024240.shtml","is_publish_highlight":false},{"id":"2314535620","title":"新华制药(000756.SZ)取得碳酸司维拉姆片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2314535620","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2314535620?lang=zh_CN&edition=full","pubTime":"2023-02-27 17:03","pubTimestamp":1677488599,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药 发布公告,近日,山公司收到国家药品监督管理局核准签发的碳酸司维拉姆片《药品注册证书》。根据《中华人民共和国药品管理法》及有关规定,经审查,本品符合药品注册的有关要求,批准注册,发给药品注册证书。据悉,碳酸司维拉姆片用于控制正在接受透析治疗的慢性肾脏病成人患者的高磷血症,属于《国家基本医疗保险、工伤保险和生育保险药品目录》乙类品种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/883177.html","is_publish_highlight":false},{"id":"2313506460","title":"抗疫概念股拉升,国内新冠疫情不确定性或带动新冠小分子需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2313506460","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2313506460?lang=zh_CN&edition=full","pubTime":"2023-02-22 10:27","pubTimestamp":1677032873,"startTime":"0","endTime":"0","summary":"中信证券发布研报称,近日我国本土首次检出XBB.1.5,若未来国内新冠疫情反复,新冠小分子需求有望增加。","market":"us","thumbnail":"https://img3.gelonghui.com/660c9-f7438420-ba25-405d-8c96-aeffce9049ba.jpg","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/660c9-f7438420-ba25-405d-8c96-aeffce9049ba.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/581378","is_publish_highlight":false},{"id":"2312284670","title":"2月17日新华制药涨停分析:新冠药物,维生素,医药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2312284670","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2312284670?lang=zh_CN&edition=full","pubTime":"2023-02-17 15:37","pubTimestamp":1676619458,"startTime":"0","endTime":"0","summary":"新华制药涨停收盘,收盘价29.58元。该股于13点7分涨停,3次打开涨停,截止收盘封单资金为1.01亿元,占其流通市值0.77%。2月17日的资金流向数据方面,主力资金净流入1.76亿元,占总成交额6.84%,游资资金净流入585.66万元,占总成交额0.23%,散户资金净流出1.82亿元,占总成交额7.06%。近5日资金流向一览见下表:该股为新冠药物,维生素,医药概念热股,当日新冠药物概念上涨2.27%,维生素概念上涨1.72%,医药概念上涨1.55%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023021700005139.shtml","is_publish_highlight":false},{"id":"2312653288","title":"异动快报:新华制药(000756)2月17日13点21分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2312653288","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2312653288?lang=zh_CN&edition=full","pubTime":"2023-02-17 13:25","pubTimestamp":1676611526,"startTime":"0","endTime":"0","summary":"2月17日盘中消息,13点21分新华制药触及涨停板。目前价格29.58,上涨10.0%。其所属行业化学制药目前上涨。该股为新冠药物,医药,维生素概念热股,当日新冠药物概念上涨2.46%,医药概念上涨1.79%,维生素概念上涨1.79%。近5日资金流向一览见下表:新华制药主要指标及行业内排名如下:新华制药个股概况:以上内容由证券之星根据公开信息整理,与本站立场无关。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023021700003478.shtml","is_publish_highlight":false},{"id":"2311468734","title":"【AH互动】新华制药(00719)AH股齐上扬 吡拉西坦注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2311468734","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2311468734?lang=zh_CN&edition=full","pubTime":"2023-02-16 10:20","pubTimestamp":1676514049,"startTime":"0","endTime":"0","summary":"山东新华制药(00719)走势强劲,最新报6.47港元,涨5.37%,成交额2725.37万港元。另外,A股新华制药(000756)同步上扬,但升势稍逊,最新报27.14元人民币,涨2.57%,成交额4.46亿元人民币。消息面上,公司近日收到国家药品监督管理局核准签发的吡拉西坦注射液(以下简称“该产品”)《药品补充申请批准通知书》,该产品通过仿制药质量和疗效一致性评价。吡拉西坦注射液适用于急、慢性脑血管病、脑外伤、各种中毒性脑病等多种原因所致的记忆减退及轻、中度脑功能障碍,也可用于儿童智能发育迟缓。吡拉西坦注射液属于《国家基本医疗保险、工伤保险和生育保险药品目录(2020 年)》乙类品种。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=e9b0bd738ba2be477eef313ff52b0632","is_publish_highlight":false},{"id":"2311790911","title":"新华制药(000756.SZ):吡拉西坦注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2311790911","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2311790911?lang=zh_CN&edition=full","pubTime":"2023-02-15 16:58","pubTimestamp":1676451522,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药 发布公告,近日,公司收到国家药品监督管理局核准签发的吡拉西坦注射液《药品补充申请批准通知书》,该产品通过仿制药质量和疗效一致性评价。据悉,吡拉西坦注射液原研为UCB Pharma公司,在欧盟上市的国家有德国、比利时、土耳其,属原研未进口品种。吡拉西坦注射液属于《国家基本医疗保险、工伤保险和生育保险药品目录》乙类品种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/876892.html","is_publish_highlight":false},{"id":"2311179141","title":"新华制药:吡拉西坦注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2311179141","media":"财联社","top":-1,"share":"https://www.laohu8.com/m/news/2311179141?lang=zh_CN&edition=full","pubTime":"2023-02-15 16:54","pubTimestamp":1676451252,"startTime":"0","endTime":"0","summary":"财联社2月15日电,新华制药公告,公司吡拉西坦注射液通过仿制药一致性评价。该药品适用于急、慢性脑血管病、脑外伤、各种中毒性脑病等多种原因所致的记忆减退及轻、中度脑功能障碍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"cailian_livestock","url":"https://www.cls.cn/detail/1267645","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.cls.cn/detail/1267645","is_publish_highlight":false},{"id":"2304688536","title":"新华制药:取得加工阿兹夫定片所需的《药品生产许可证》C证","url":"https://stock-news.laohu8.com/highlight/detail?id=2304688536","media":"财联社","top":-1,"share":"https://www.laohu8.com/m/news/2304688536?lang=zh_CN&edition=full","pubTime":"2023-01-18 16:58","pubTimestamp":1674032329,"startTime":"0","endTime":"0","summary":"【新华制药:取得加工阿兹夫定片所需的《药品生产许可证》C证】财联社1月18日电,新华制药公告,2023年1月18日,公司取得山东省药品监督管理局颁发的关于公司生产加工阿兹夫定片所需的《药品生产许可证》C证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"cailian_livestock","url":"https://www.cls.cn/detail/1244680","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.cls.cn/detail/1244680","is_publish_highlight":false},{"id":"2302385863","title":"新华制药(000756.SZ):OAB-14干混悬剂药物临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2302385863","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2302385863?lang=zh_CN&edition=full","pubTime":"2023-01-12 16:49","pubTimestamp":1673513347,"startTime":"0","endTime":"0","summary":"据悉,OAB-14是一类全新作用机制的抗AD候选药物,在已完成的药效学研究表明OAB-14能显著减少脑内β淀粉样蛋白沉积。目前靶向Aβ清除的药物只有FDA批准的渤健/卫材的单抗药物aducanumab,但尚无靶向Aβ清除的多靶点小分子抗AD药物进入临床试验或上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/861026.html","is_publish_highlight":false},{"id":"2302728613","title":"板块异动 | 阿兹夫定参与医保药品目录谈判成功 新冠药概念股尾盘拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=2302728613","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2302728613?lang=zh_CN&edition=full","pubTime":"2023-01-09 14:48","pubTimestamp":1673246905,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,1月9日,受阿兹夫定参与医保药品目录谈判成功消息影响,A股新冠药概念股拉升,截至发稿,广生堂直线拉涨7%,众生药业、新华制药、舒泰神、盘龙药业等股拉升上涨。1月8日,2022年国家医保药品目录谈判工作正式结束。其中,阿兹夫定片、清肺排毒颗粒谈判成功,Paxlovid因生产企业辉瑞报价高未能成功。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/858931.html","is_publish_highlight":false},{"id":"2301757221","title":"不用抢了?退烧药、抗原短缺状况已缓解 京沪基层正陆续配备新冠口服药|传真","url":"https://stock-news.laohu8.com/highlight/detail?id=2301757221","media":"财联社","top":-1,"share":"https://www.laohu8.com/m/news/2301757221?lang=zh_CN&edition=full","pubTime":"2023-01-06 20:09","pubTimestamp":1673006994,"startTime":"0","endTime":"0","summary":"对于近段时间供应紧张的涉疫物资,财联社记者实地走访和线上访问了诸多涉疫物资生产、经营和使用企业、单位,总体来看,退烧药物和抗原检测试剂短缺状况已经得到较大缓解,消费者已经可以通过多种渠道购买。","market":"sh","thumbnail":"https://img.cls.cn/images/20230106/5Q3vq8EthW.jpg@!thumb_flash","type":0,"news_type":0,"thumbnails":["https://img.cls.cn/images/20230106/5Q3vq8EthW.jpg@!thumb_flash"],"rights":{"source":"cls_stock","url":"https://m.cls.cn/depth/1233396","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://m.cls.cn/depth/1233396","is_publish_highlight":false},{"id":"2301265250","title":"格隆汇公告精选︱康希诺:新冠mRNA疫苗在临床研究中取得了积极的阶段性数据;尚太科技:锂离子电池负极材料项目仍处于论证阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2301265250","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2301265250?lang=zh_CN&edition=full","pubTime":"2023-01-06 00:11","pubTimestamp":1672935103,"startTime":"0","endTime":"0","summary":"振华新材(688707.SH):2022年度净利预增195.70%-215.09%;数源科技(000909.SZ):目前没有与\"元宇宙\"相关的业务","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/108.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/108.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/572676","is_publish_highlight":false}],"profile":{"ret":0,"listingDate":"1997-08-06","address":"山东省淄博市张店区高新技术产业开发区化工区","stockEarnings":[{"period":"1week","weight":-0.0121},{"period":"1month","weight":-0.1551},{"period":"3month","weight":-0.2596},{"period":"6month","weight":0.4608},{"period":"1year","weight":1.5427},{"period":"ytd","weight":-0.1585}],"companyName":"山东新华制药股份有限公司","boardCode":"AI0027","perCapita":"2935股","boardName":"医药制造业","registeredCapital":"67388万元","compareEarnings":[{"period":"1week","weight":0.0051},{"period":"1month","weight":-0.0048},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.0678},{"period":"1year","weight":0.0122},{"period":"ytd","weight":0.0525}],"survey":" 山东新华制药股份有限公司主要从事开发、制造及销售化学原料药、制剂以及化工产品;公司的主要产品有解热镇痛类原料药、片剂、针剂、胶囊剂、医药中间体。公司拥有技术创新优势,现为高新技术企业、国家火炬计划重点高新技术企业、国家火炬计划生物医药产业基地骨干企业,拥有国家级企业技术中心,建有企业博士后科研工作站。“基于产业化关键技术的咖啡因绿色制备体系构建与规模开发”荣获2018年度山东省科学技术进步二等奖。上半年获得专利授权10件。公司被公示为“山东省技术创新示范企业”,被评为山东人才工作先进单位。","serverTime":1680018893205,"listedPrice":3.45,"stockholders":"150106人(较上一季度增加39.94%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.12.1","shortVersion":"4.12.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新华制药,000756,新华制药股票,新华制药股票老虎,新华制药股票老虎国际,新华制药行情,新华制药股票行情,新华制药股价,新华制药股市,新华制药股票价格,新华制药股票交易,新华制药股票购买,新华制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}